Arrowhead Research reported $129.79M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Arrowhead Research USD 129.79M 55.92M Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Ligand Pharmaceuticals USD 67.67M 189.22M Jun/2025
Merck USD 8.01B 622M Jun/2025
Moderna USD 1.28B 344M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
TG Therapeutics USD 278.86M 146.72M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025
Xencor USD 44.44M 4.77M Jun/2025